Holen Sie sich die Stockscreener-App
1.64
2.37%
-0.05
Lifeward Ltd Aktie (LFWD) Neueste Nachrichten
Lifeward Ltd. (LFWD): Among the Penny Stocks With Huge Upside Potential According to Analysts - Insider Monkey
10 Penny Stocks With Huge Upside Potential According To Analysts - Insider Monkey
Lifeward Stock Falls Despite FDA Clearance of ReWalk 7 Exoskeleton - TradingView
Lifeward gains FDA clearance for new ReWalk exoskeleton - Investing.com
Sector Update: Health Care Stocks Softer Thursday Afternoon -March 13, 2025 at 02:06 pm EDT - Marketscreener.com
Sector Update: Health Care -March 13, 2025 at 01:43 pm EDT - Marketscreener.com
What's Going On With Lifeward Shares Thursday?Lifeward (NASDAQ:LFWD) - Benzinga
FDA Approval of ReWalk7 Sends Lifeward (LFWD) Stock Climbing - Stocks Telegraph
Lifeward announces FDA clearance for ReWalk 7 exoskeleton - TipRanks
Lifeward Receives FDA Clearance for ReWalk 7 Exoskeleton; Shares Jump -March 13, 2025 at 09:41 am EDT - Marketscreener.com
Lifeward gains FDA clearance for new ReWalk exoskeleton By Investing.com - Investing.com UK
FDA Issues Clearance for ReWalk 7 Exoskeleton - GlobeNewswire
Revolutionary ReWalk 7 Exoskeleton Gets FDA Green Light, Medicare Coverage Ready - StockTitan
Nasdaq Down Over 100 Points; US Producer Inflation Stalls In February - Benzinga
Lifeward stock holds Buy rating and $13 target from H.C. Wainwright - Investing.com Australia
Positive Outlook for Lifeward Driven by Strategic Partnerships and Market Expansion Initiatives - TipRanks
Lifeward stock holds Buy rating and $13 target from H.C. Wainwright By Investing.com - Investing.com South Africa
Lifeward reports operating loss of USD 15.2M in Q4 2024 - Medical Buyer
Lifeward Ltd (LFWD) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ... - Yahoo Finance
Lifeward Ltd. Reports Strong 2024 Revenue Growth - TipRanks
Lifeward: Q4 Earnings Snapshot - The Washington Post
Lifeward earnings missed by $0.19, revenue fell short of estimates - Investing.com South Africa
Lifeward Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Lifeward (LFWD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Lifeward Ltd Reports Q4 2024 Earnings: EPS of -$1.73 Misses Esti - GuruFocus.com
Lifeward Ltd. Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Lifeward reports Q4 EPS ($1.73) vs (66c) last year - TipRanks
Lifeward Ltd. Reports Record Annual Revenue of $25.7 Million and Launches 2025 Sustainable Growth Plan - Nasdaq
Lifeward expects Q1 revenue to be the lowest of the year - TipRanks
Lifeward and CorLife Finalize Partnership to Expand Workers’ Compensation Access to ReWalk Exoskeleton - GlobeNewswire
Lifeward and MYOLYN expand contract for home therapy system By Investing.com - Investing.com Canada
Lifeward, MYOLYN expand partnership to enhance patient access to MyoCycle - TipRanks
Lifeward and MYOLYN expand contract for home therapy system - Investing.com India
Lifeward and MYOLYN Expand Partnership to Enhance Patient Access to MyoCycle FES Cycling Therapy System for Home Use - The Manila Times
Lifeward Ltd. and MYOLYN Expand Partnership to Enhance Access to MyoCycle FES Therapy for Home Rehabilitation - Nasdaq
Lifeward and MYOLYN Expand Partnership to Enhance Patient - GlobeNewswire
Lifeward Secures Exclusive Rights to Transition MyoCycle Therapy Patients from Clinic to Home - StockTitan
Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025 - GlobeNewswire
1 Healthcare Stock to Own for Decades and 2 to Ignore - The Globe and Mail
Medical Tech Leader Lifeward Sets Date for 2024 Financial Results Reveal - StockTitan
Rehabilitation Robots Market Size Expected to Reach USD 1776.24 Mn by 2034 - GlobeNewswire Inc.
Lifeward Ltd expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Lifeward CEO Larry Jasinski to step down - MSN
Lobbying Update: $15,000 of LIFEWARD (FORMERLY REWALK ROBOTICS INC.) lobbying was just disclosed - Nasdaq
0.62%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):